Mesalazine Regulates DUSP1, DUSP4, and DUSP5 Expression in Colorectal Cancer: In Vitro and Bioinformatic Evidence.

Area of Science:

• Molecular Biology
• Cancer Research
• Pharmacology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
• Dysregulation of mitogen-activated protein kinase (MAPK) signaling pathways is implicated in CRC development.
• Dual-specificity phosphatases (DUSPs) are key regulators of MAPKs, balancing cell proliferation and apoptosis.

Purpose of the Study:

• To investigate the impact of mesalazine (MES) on DUSP family members in normal and colorectal cancer cells.
• To elucidate the molecular mechanisms of mesalazine's potential anticancer effects in CRC.

Main Methods:

• Microarray analysis to assess gene expression changes in response to mesalazine.
• Enzyme-linked immunosorbent assay (ELISA) to quantify protein level changes.
• Experiments conducted on normal colon epithelial cells (CCD-841CoN) and colorectal cancer cells (DLD-1).

Main Results:

• Mesalazine treatment altered the expression of 24 transcripts in colon cells.
• DUSP4 and DUSP5 expression was upregulated in DLD-1 cancer cells but downregulated in CCD-841CoN normal cells.
• ELISA confirmed a significant increase in DUSP5 protein in mesalazine-treated cancer cells.

Conclusions:

• Mesalazine exhibits differential modulation of DUSP gene expression between normal and malignant colon cells.
• These findings suggest a mechanism for mesalazine's antiproliferative and pro-apoptotic effects via MAPK pathway regulation.
• The study provides novel insights into mesalazine's molecular action against colorectal cancer.